

Anti-C-Raf (C-terminus) Antibody

Catalog # AN1933

Product Information

Application WB
Primary Accession P04049
Host Rabbit

Clonality Rabbit Polyclonal

Isotype IgG **Calculated MW** 73052

Additional Information

Gene ID 5894 Other Names Raf1, CRaf

Dilution WB~~1:1000

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions Anti-C-Raf (C-terminus) Antibody is for research use only and not for use in

diagnostic or therapeutic procedures.


Shipping Blue Ice

Background

The Ras-Raf-MAP kinase signaling pathway is involved in control of cell proliferation and differentiation. The Raf kinase family includes A-Raf, B-Raf, and C-Raf. Each family member has three highly conserved regions (CR1-3). The N-terminal CR1 contains the Ras-GTP-binding domain. The CR2 contains a negative regulatory serine residue (C-Raf (S259)/B-Raf(S365)) that may bind 14-3-3 proteins. The CR3 is the catalytic domain that contains phosphorylation sites for Raf-regulating enzymes within two segments, the N-region and the activation segment. Activation of C-Raf involves phosphorylation at many sites including Ser-338, Tyr-341, and multiple catalytic domain sites. EGF receptor activation leads to phosphorylation of Ser-471, which is critical for C-Raf kinase activity and is required for interaction with MEK. In B-Raf, the corresponding conserved site is Ser-578, and mutation of this residue to alanine produces an inactivate kinase. Thus, this Raf phosphorylation site may be critical for kinase activity and may be important for MEK binding and activation

Images

Western blot of GST fusion protein containing human C-Raf. The blot was probed with polyclonal anti-C-Raf (C-terminus) antibody in the presence (lanes 2-4) or absence (lane 1) of C-Raf (C-terminus) blocking peptide



(lane 2), C-Raf (Ser-471) peptide (lane 3), or unrelated peptide (lane 4).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.